lm-061
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 17, 2021 (NCT04737122)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04882176 | Phase 1/Phase 2 (Phase 2) | May 20, 2021 | LaNova Medicines Limited |
| NCT04737122 | Phase 1 | May 17, 2021 | LaNova Medicines Limited, Peninsula & South Eastern Haematology & Oncology Group, Southern Oncology Clinical Research Unit, St. George Private Hospital |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| LaNova Medicines Limited | For profit | 2 | 2 | 2 | 2021 |
| Peninsula & South Eastern Haematology & Oncology Group | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Southern Oncology Clinical Research Unit | For profit | 1 | 0 | 1 | 2021 |
| St. George Private Hospital | Academic/Hospital | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1